While some batches of Taxotere® have been recalled, the drug is still on the market and regularly used in chemotherapy treatments. There have been at least two widespread recalls of the medication, including:
- April 2016. Drugmaker Sanofi-Aventis recalled several batches of Taxotere in the United Kingdom due to a manufacturing error. According to the company, a software failure may have caused some of the alcohol in the injectable product to evaporate, making the drug more concentrated. The recalled batches were labeled #5F219A and carried an expiration date of August 31, 2018.
- March 2001. Taxotere was also recalled in the United States in 2001 due to a labeling error on some of the vials. Some 20-mg vials were reportedly labeled as “diluent” vials, suggesting that they be diluted before administration, making the drug less potent.
Although many women have suffered permanent hair loss due to Taxotere, the U.S. Food and Drug Administration (FDA) has not issued a recall of the medication due to the side effect. Instead, the agency has requested that a warning about permanent alopecia (hair loss) be placed on the drug label.
Generic Versions of Taxotere May Also Carry Hair Loss Risks
Taxotere can be administered as a treatment for many different types of cancer, but is most commonly administered to women who have been diagnosed with early-stage breast cancer. Even if these women have checked their chemotherapy records to see if they were treated with Taxotere, there are now several different generic versions of the medication under a variety of different names.
If your hair loss has persisted for months or years after your treatment with Taxotere, you may be able to file a suit against the drugmaker for your suffering. Many women who have experienced permanent alopecia say they were not adequately warned about the risk of permanent hair loss, and if they had been, they may have chosen a different chemotherapy medication. Contact us today to tell your story to an attorney and have us begin an investigation into your case.